Filters
The novel switch-control tyrosine kinase inhibitor ripretinib delivered a clinically meaningful benefit for patients with gastrointestinal stromal tumours (GISTs) following crossover from placebo, and had a safety profile consistent with that observed in the double-blind phase, according to the results of the crossover analysis of the INVICTUS trial presented at ESMO GI 2020.
A trivalent vaccine against hepatitis (hep B) is safe and effectively elicits robust immune response compared with a monovalent Hep B vaccine, according to the PROTECT and CONSTANT studies presented during the 2020 digital ILC.
A healthy lifestyle pattern, especially maintaining a healthy weight, may lower the risk of developing symptomatic gallstone diseases, as indicated by findings from two large prospective studies.
Older patients (aged ≥65 years) with unresectable hepatocellular carcinoma (HCC) may derive greater survival benefit with an atezolizumab + bevacizumab combination compared with sorafenib, according to results of a subgroup analysis of the IMbrave150 trial presented at ESMO GI 2020.
Drinking coffee, tea, or soda may trigger gastroesophageal reflux, whereas water, juice, or milk does not, according to a study.
Safety data from the phase III IMbrave150 trial reinforce the previously reported favourable safety profile of atezolizumab-bevacizumab compared with sorafenib for unresectable hepatocellular carcinoma (HCC).
In patients with advanced hepatocellular carcinoma (HCC), first-line treatment with nivolumab may confer greater overall survival (OS) than sorafenib, according to updated results of the phase III CheckMate 459* study.
Hope for a hepatitis B virus cure becomes manifest as multiple drugs from recent clinical trials show potential in transforming the battle against the disease.
Treatment with sorafenib plus hepatic arterial infusion chemotherapy (SoraHAIC) for advanced hepatocellular carcinoma (HCC) has been shown to be safe and effective in a recent study.
The use of continuous flow ventricular assist devices (VADs), regardless of the type, does not appear to exacerbate the risk of gastrointestinal bleeding (GIB), according to a recent meta-analysis.
